Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 4;11(21):6545.
doi: 10.3390/jcm11216545.

Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19)

Jeremie Zerbit  1 , Marion Detroit  2 , Sylvie Chevret  3 , Frederic Pene  4   5 , Charles-Edouard Luyt  6   7 , Jade Ghosn  8 , Frederic Eyvrard  9 , Guillaume Martin-Blondel  10   11 , Benjamine Sarton  12   13 , Raphael Clere-Jehl  14 , Pierre Moine  15   16 , Amelie Cransac  17 , Pascal Andreu  18 , Marie Labruyère  18 , Laetitia Albertini  19 , Jean-François Huon  20 , Pauline Roge  21 , Lise Bernard  22 , Magali Farines-Raffoul  23 , Maxime Villiet  24 , Arnaud Venet  25 , Louis Marie Dumont  26 , Jean-Daniel Kaiser  27   28 , Claire Chapuis  29 , François Goehringer  30 , François Barbier  31 , Stephane Desjardins  32 , Younes Benzidi  33 , Nora Abbas  34 , Corinne Guerin  34 , Rui Batista  34 , Jean-François Llitjos  5   35 , Marie Kroemer  2   36
Affiliations

Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19)

Jeremie Zerbit et al. J Clin Med. .

Abstract

Background: Given the rapidly evolving pandemic of COVID-19 in 2020, authorities focused on the repurposing of available drugs to develop timely and cost-effective therapeutic strategies. Evidence suggested the potential utility of remdesivir in the framework of an early access program. REMDECO-19 is a multicenter national cohort study assessing the ability of remdesivir to improve the outcome of patients hospitalized with COVID-19.

Methods: We conducted a retrospective real-life study that included all patients from the early access program of remdesivir in France. The primary endpoint was the clinical course evolution of critically ill and hospitalized COVID-19 patients treated with remdesivir. Secondary endpoints were the SOFA score evolution within 29 days following the admission and mortality at 29 and 90 days.

Results: Eighty-five patients were enrolled in 22 sites from January to April 2020. The median WHO and SOFA scores were respectively reduced by two and six points between days 1 and 29. Improvement in the WHO-CPS and the SOFA score were observed in 83.5% and 79.3% of patients, respectively, from day 10. However, there was no effect of remdesivir on the 90-day survival based on the control cohort for hospitalized COVID-19 patients with invasive ventilation.

Conclusions: SOFA score appeared to be an attractive approach to assess remdesivir efficacy and stratify its utilization or not in critically ill patients with COVID-19. This study brings a new clinical benchmark for therapeutic decision making and supports the use of remdesivir for some hospitalized COVID-19 patients.

Keywords: COVID-19; SARS-CoV-2; pneumonia; remdesivir; survival.

PubMed Disclaimer

Conflict of interest statement

F.B. reports consulting and lecture fees from MSD and lecture fees from Biomérieux, outside the scope of the submitted work. J.Z. reports consulting fees from AstraZeneca, outside the scope of the submitted work. J.G. reports grants from Gilead and ViiVHealthcare and personal fees from MSD, Gilead, Astra Zeneca, Roche, and ViiVHealthcare, outside the scope of the submitted work. F.P. reports consulting fees and grants from Alexion Pharma and consulting and personal fees from Gilead outside the scope of the submitted work.

Figures

Figure 1
Figure 1
Correction of confusion bias by weighting. (A) Distribution of the propensity score between groups on the original basis. (B) Correction of the imbalances according to the types of weighting. WBC, white blood cells; BMI, body mass index.
Figure 2
Figure 2
Oxygen Support Flow Chart.
Figure 3
Figure 3
WHO Score Double-Entry Board. WHO score at baseline and after remdesivir treatment; Number (%).
Figure 4
Figure 4
SOFA Scores Heatmap. SOFA scores at day 1, 3, 8, 11, 15, and 29. Increasingly blue colors mean improved SOFA scores compared to J1; increasingly red colors mean worsened SOFA scores compared to J1. Each row corresponds to a patient.
Figure 5
Figure 5
SOFA and WHO Scores Box Plot. SOFA and WHO scores at day 1, 3, 8, 11, 15, and 29 for all patients and regarding oxygen support.
See this image and copyright information in PMC

References

    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed
    1. Semenzato L., Botton J., Drouin J., Cuenot F., Dray-Spira R., Weill A., Zureik M. Chronic Diseases, Health Conditions and Risk of COVID-19-Related Hospitalization and in-Hospital Mortality during the First Wave of the Epidemic in France: A Cohort Study of 66 Million People. Lancet Reg. Health—Eur. 2021;8:100158. doi: 10.1016/j.lanepe.2021.100158. - DOI - PMC - PubMed
    1. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. - DOI - PMC - PubMed
    1. Rizk J.G., Forthal D.N., Kalantar-Zadeh K., Mehra M.R., Lavie C.J., Rizk Y., Pfeiffer J.P., Lewin J.C. Expanded Access Programs, Compassionate Drug Use, and Emergency Use Authorizations during the COVID-19 Pandemic. Drug Discov. Today. 2021;26:593–603. doi: 10.1016/j.drudis.2020.11.025. - DOI - PMC - PubMed
    1. RECOVERY Collaborative Group Dexamethasone in Hospitalized Patients with COVID-19. N. Engl. J. Med. 2021;384:693–704. doi: 10.1056/NEJMoa2021436. - DOI - PMC - PubMed

LinkOut - more resources